** ANNOUNCEMENT **
The Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK have announced the approval of Seladelpar (Livdelzi) to be used in the treatment of adult patients in the UK with Primary Biliary Cholangitis.
This is exciting news as it provides an additional second line therapy to be used in combination with Ursodeoxycholic Acid (UDCA) for patients who have had an inadequate response to UDCA alone or as a new treatment for patients who are unable to tolerate UDCA. We welcome this decision by MHRA and look forward to seeing what happens with NICE in due course.
Read more here in their press release: ow.ly/Iwwu50UNG19
#pbc #PrimaryBiliaryCholangitis #SecondLineTherapy